Merck (MRK) PT Raised to $74 at JPMorgan

JPMorgan raised its price target on Merck (NYSE: MRK) to $74.00 (from $72.00) while maintaining a Overweight rating.

Analyst Chris Schott remains positive on the equity and sees further potential for Keytruda to generate upside through 2018 and into 2019 citing both the ramp in lung along with data in other tumor types. The analyst is now forecasting Keytruda sales of $6.5 billion in 2018 and raises his 2019/2020 sales forecasts to $8.0 billion & $12 billion respectively.

You May Also Be Interested In

• Incyte (INCY) PT Raised to $105 at Truist Securities
• Allegro MicroSystems (ALGM) PT Raised to $70 at TD Cowen: 'Secular + Cyclical Growth Combo'
• Devon Energy (DVN) PT Lowered to $67 at Wolfe Research: Activist Toms interest positive